BioPharma Resources

Drug Trial Radar · NCT07427394

Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer

A Phase IIa, Open-label Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of Camizestrant in Combination With Atirmociclib in Participants With ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1b)

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

May 6, 2026

Primary completion

Dec 28, 2027

Study completion Dec 28, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Feb 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.

Conditions

  • Advanced Breast Cancer

Interventions

  • CamizestrantDrug

    Camizestrant will be administered orally.

  • AtirmociclibDrug

    Atirmociclib will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs) and serious AEsTime frame: Up to Post-Treatment Follow up (Day 30 Post Dose)

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Research Site

    St Louis, Missouri · Recruiting

  • Research Site

    East Providence, Rhode Island · Recruiting

  • Research Site

    Nashville, Tennessee · Recruiting

  • Research Site

    Cambridge, United Kingdom · Recruiting

  • Research Site

    London, United Kingdom · Recruiting

  • Research Site

    Manchester, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.